Organogenesis Holdings Inc. applauded the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule. The proposal suggests a per-square-centimeter payment methodology based on FDA classification.
The company believes this new payment structure will curb abuse under the current system and stabilize the market, ensuring a consistent payment approach across all sites of care. Organogenesis is particularly pleased that CMS has recognized the clinical differentiation of PMA products, which are proven to reduce life-threatening amputations and complications.
Organogenesis, with its diverse portfolio including technologies in each FDA category, believes it is well-positioned for future growth in this evolving wound care market. The company remains committed to working with CMS to refine these policies to promote long-term stability and expand access to necessary PMA products, while also reducing overall Medicare costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.